optaflu vaccine suspension for injection 0.5ml pre-filled syringes
seqirus vaccines ltd - influenza virus surface antigens - suspension for injection
aflunov(r) prepandemic influenza vaccine, h5n1 (surface antigen, inactivated, adjuvanted) 0.5ml pre-filled syringe
seqirus pty ltd - influenza virus haemagglutinin -
nobivac pi live vaccine
intervet australia pty limited - canine parainfluenza virus - parenteral liquid/solution/suspension - canine parainfluenza virus vaccine-viral active 0.0 p - immunotherapy - dog | bitch | castrate | puppy - canine parainfluenza | respiratory disease
influvac
viatris limited - influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180); influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 15ug (a/singapore/infimh-16-0019/2016, nib-104); influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) - suspension for injection - 0.5 ml - active: influenza virus a/michigan/45/2015 (h1n1) pdm09 - like strain 15ug (a/singapore/gp1908/2015, ivr-180) influenza virus a/singapore/infimh-16-0019/2016 (h3n2) - like strain 15ug (a/singapore/infimh-16-0019/2016, nib-104) influenza virus b/phuket/3073/2013 - like strain 15ug (b/phuket/3073/2013, wild type) excipient: calcium chloride dihydrate dibasic sodium phosphate dihydrate magnesium chloride hexahydrate monobasic potassium phosphate potassium chloride sodium chloride water for injection - for the prevention of influenza virus, types a and b in adults and children older than 6 months in accordance with the recommendations in the national immunisation guideline.
vaxigrip vaccine
sanofi-aventis new zealand limited - influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]); ; influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]); ; influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]); - solution for injection - 10µg/15µg/15µg per dose - active: influenza virus a/wellington/i/2004(h3n2)-like strain 10ug ([influenza virus a/wellington/i/2004 ivr-139(10 µg/ha)]) influenza virus b/shanghai/361/2002-like strain 15ug ([b/jiangsu/10/2003 (15µg/ha)]) influenza virus haemagglutinin type a/new caledonia/20/99 h1n1-like strain 15ug ([a/new caledonia/20/99 ivr-116 (15µg/ha)]) excipient: dibasic sodium phosphate dihydrate monobasic potassium phosphate neomycin sodium chloride water for injection
rotateq (rotavirus vaccine live oral pentavalent)
merck sharp & dohme (israel - 1996) company ltd, israel - rotavirus g1 reassortant; rotavirus g2 reassortant; rotavirus g3 reassortant; rotavirus g4 reassortant; rotavirus p1a[8] reassortant - oral solution - rotavirus p1a[8] reassortant 2.3 x10 ^6 iu/dose; rotavirus g2 reassortant 2.8 x10 ^6 iu/dose; rotavirus g4 reassortant 2.0 x10^ 6 iu/dose; rotavirus g3 reassortant 2.2 x10 ^6 iu/dose; rotavirus g1 reassortant 2.2 x10 ^6 iu/dose - rota virus diarrhea vaccines - rotateq is indicated for the prevention of rotavirus gastroenteritis in infants and children caused by types g1, g2, g3, g4, and g9 when administered as a 3-dose series to infants between the ages of 6 to 32 weeks. the first dose of rotateq should be administered between 6 and 12 weeks of age
idflu
sanofi pasteur s.a. - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of idflu should be based on official recommendations.
intanza
sanofi pasteur europe - influenza virus (inactivated, split) of the following strains:a/california/7/2009 (h1n1)pdm09 - like strain (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - like strain (b/brisbane/60/2008, wild type) - influenza, human; immunization - vaccines - prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.the use of intanza should be based on official recommendations.
fluvax inactivated influenza vaccine (split virion) thiomersal free 0.5 ml injection syringe 2019
seqirus pty ltd - influenza virus haemagglutinin -
fluvax inactivated influenza vaccine (split virion) thiomersal free 0.5ml injection syringe with attached needle 2019
seqirus pty ltd - influenza virus haemagglutinin -